Aurobindo, Lannett deal requires divestiture of four drug products, US FTC says
( June 18, 2026, 17:38 GMT | Official Statement) -- MLex Summary: Aurobindo Pharma Limited is required to divest four generic drug products to complete its $250 million acquisition of Lannett Company Inc., according to an order released by the US Federal Trade Commission. Terms of the FTC's consent order require four drug products — Mycophenolate mofetil oral suspension, Niacin extended release tablets, Pilocarpine tablets and Rabeprazole sodium delayed release tablets —to be divested to Quagen Pharmaceuticals LLC. The FTC voted 2-0 to issue the complaint and accept the consent agreement of public comment.See document attached and release below....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.